Techbio Today

The front page of AI-driven biology

TechBio Today, today’s edition

Today’s spotlight

Selected across News, Publications, and Preprints

  • News

    City Therapeutics prices upsized $200 million Nasdaq IPO

    City Therapeutics sold 11.1 million shares at $18 each to raise $200 million in gross proceeds to advance its pipeline of RNA-interference (RNAi) drugs, which turn off disease-linked genes. The biotech earmarked $30 million to take its Factor XI-targeting candidate, CITY-FXI, through Phase 1 and into mid-stage testing to prevent blood clots after knee surgery. Another $60 million will fund early trials for two liver-targeted siRNA assets designed to treat ocular diseases, including Stargardt disease, and anemia.

    Fierce Biotech

This week’s top AI x bio headlines

From News, the past seven days

  1. AstraZeneca taps insitro's AI platform for liver and heart drug targets

    Fierce Biotech

  2. Iambic Therapeutics raises $150 million in Nasdaq debut

    BioPharma Dive

  3. Zealand Pharma and Generate partner on AI-designed obesity drugs in $1.2 billion pact

    Reuters

  4. DeepMind watermarks AI-designed proteins without reducing target binding

    Yahoo Finance

  5. Gilead licenses solid-tumor T cell engagers from Vir in $1.9 billion pact

    Fierce Biotech

View all news →

Publications

View all →
  • Upgraded diffusion model scaffolds intricate enzyme active sites from scratch

    University of Washington researchers have introduced RFdiffusion3, a generative model that uses free-atom diffusion to build custom protein and RNA structures around precise geometric constraints.

    Science
  • Language models pull standardized rare-disease symptoms directly from patient notes

    Researchers built RARE-PHENIX, an automated framework that reads unstructured clinical text, standardizes symptoms into formal Human Phenotype Ontology terms, and ranks them by diagnostic importance.

    npj Digital Medicine
  • AI scans link brown fat activity to lower psychiatric disease rates and flag candidate drugs

    An artificial intelligence system quantified human brown adipose tissue activity across clinical scans, revealing strong associations between active brown fat, improved metabolic profiles, and reduced rates of psychiatric illness.

    Nature
  • Graph-based method parses tissue architecture across spatial scales

    SpatialZoomer uses spectral graph theory to analyze spatial transcriptomics data simultaneously at individual cell resolution and across broad tissue domains.

    Nature Biomedical Engineering

View all publications →

Preprints

View all →

View all preprints →

TechBio Today’s AI x Bio Feed

Follow @TechBioTodaySee the list →

Upcoming conferences, seminars, and events

Send feedback